PDS Biotech Announces Interim Safety and Immune Response Data From Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined With Docetaxel to Treat Metastatic Prostate Cancer
PDS Biotech Announces Interim Safety and Immune Response Data From Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined With Docetaxel to Treat Metastatic Prostate Cancer
PDS Biotechnology Corporation (NASDAQ:PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company's proprietary T cell activating platforms, today announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care (SOC) chemotherapy, docetaxel, to treat metastatic castration sensitive (mCSPC) and castration resistant (mCRPC) prostate cancer. The data will be featured in an oral presentation by Ravi A. Madan, MD, Head, Prostate Cancer Clinical Research Section, Genitourinary Malignancies Branch, Center for Cancer Research of the National Cancer Institute, an Institute of the National Institutes of Health, at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023) in Athens, Greece.
亞洲網加利福尼亞州聖克拉拉10月23日電PDS生物技術公司(納斯達克股票代碼：PDSB)(PDS Biotech or本公司)是一家臨床階段免疫治療公司，該公司正在開發基於公司專有T細胞激活平臺的靶向癌症免疫療法和傳染疫病苗的不斷增加的管道。該公司今天宣佈，評估PDS0301的人類首個1/2期臨床試驗的中期安全性和免疫反應數據。這些數據將由拉維·A·馬丹博士在希臘雅典舉行的第11屆國際細胞因數和幹擾素學會(細胞因數2023)年會上口頭介紹，他是國家癌症研究所癌症研究中心泌尿生殖系惡性腫瘤分部前列腺癌臨床研究科科長。